Haleon (HAM:H6D) FFO


HAM:H6D Haleon PLC HAM:H6D
74 GF Score
Price €8.05
GF Value €8.39
! 3 Warning Signs
View Full Analysis

What is Haleon FFO?

FFO (Funds from operations) only applies to REITs.

HAM:H6D
74GF Score
Haleon PLC HAM:H6D
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Haleon (HAM:H6D) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be undervalued. The current stock price of €8.05 is trading 4.1% below its estimated GF Value™ of €8.39.

Key valuation signals for HAM:H6D:

  • FFO:
  • GF Value™: €8.39 vs. price of €8.05 (4.1% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the HAM:H6D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
74GF Score

Get the complete analysis for HAM:H6D

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.05
Price
€8.39
GF Value